News

Health Canada has granted priority review to an application that seeks to expand the approval of Trikafta to cover children with cystic fibrosis (CF) as young as 6 years. “We are pleased that [the application] has been accepted for Priority Review by Health Canada and we look forward…

Young children with cystic fibrosis (CF), relative to age-matched peers with disorders also affecting the lungs, show differences in bacterial communities and inflammation of the lower airways starting at around age 2, a study reported. A lesser variety of bacterial classes and more inflammation in the lower airways —…

Funding totaling £750,000 ($1,028,550) for a Strategic Research Centre (SRC) in the United Kingdom is expected to speed development of antibiotics to battle the lung infections that most cystic fibrosis (CF) patients experience. The four-year award from the Cystic Fibrosis Trust and the Cystic Fibrosis Foundation…

Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution, a new study reveals. “A long-standing lore in the cystic fibrosis field says that each patient’s infection tells a unique story, and that Pseudomonas evolves in unpredictable ways,” Jennifer Bomberger, PhD, said…

Treatment with LungFit GO, an inhaled form of nitric oxide that can be self-administered at home, has so far been well-tolerated in a pilot clinical trial testing the investigational medication in adults with or without cystic fibrosis (CF). The ongoing trial involves patients with lung infections caused by…

Boehringer Ingelheim has taken legal steps giving it the lead role in further development of a long-lasting, inhalation gene therapy for cystic fibrosis (CF), called BI 3720931, that stems from a public-private research effort begun in 2018. The 2018 agreement brought together Boehringer, the U.K. Cystic Fibrosis…

A team of researchers from the Michigan State University (MSU) College of Human Medicine and Spectrum Health will use a $2.1 million grant from the National Institutes of Health (NIH) to advance preclinical research on a gene therapy for cystic fibrosis (CF). The four-year award was given to the…

Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…

MRI scans may help to reveal subtle changes in certain areas of the brain among people with cystic fibrosis (CF), a study found. The affected areas are involved in mood and cognition, which were found to be altered relative to people without the genetic disease. “CF patients exhibited significant…

The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic research center (SRC) dedicated to studying gene editing as a potential treatment strategy for cystic fibrosis (CF). “Making gene editing a reality for people with CF will take the…